抗gp210及sp100抗体在原发性胆汁性肝硬化患者中的临床研究

Clinical research of anti-gp210 and anti-sp100 antibody in primary biliary cirrhosis patients

目的探讨抗gp210、sp100抗体检测在原发性胆汁性肝硬化(PBC)患者的相关性及临床意义。方法 53例原发性胆汁性肝硬化及168例非原发性胆汁性肝硬化(非PBC)患者及50例健康对照采用免疫印迹法检测抗gp210和sp100自身抗体并观察其临床评价指标,对其结果进行回顾性分析。结果 (1)53例PBC患者采用免疫印迹法检测gp210和sp100等自身抗体结果显示其阳性率分别为41.5%和17.0%;与非PBC和对照组比较,P<0.01有非常显著性意义。(2)53例PBC患者检测gp210和sp100等自身抗体与非PBC及对照组比较,其临床评价指标结果显示敏感性为41.5%和17.0%,特异性为97.2%和99.5%。结论 PBC患者检测抗gp210和抗sp100抗体,对PBC的诊断及治疗具有重要的作用,有助于提高PBC诊疗水平。

Absract： Objective To explore the relativity and the clinical significance of testing anti-gp210 and anti-spl00 antibody in patients with primary biliary cirrhosis （PBC）. Methods Samples from 53 eases of PBC patients, 168 cases of non-PBC patients and 50 cases of healthy people were collected and autoimmune antibodies including anti-gp210 and spl00 antibodies were tested with Western blotting. Then, the clinical evaluation indexes were observed and the results were analyzed retrospectively. Results The positive rates of anti-gp210 and spl00 were 41.5% and 17.0%, respectively, in 53 cases of PBC patients tested with Western blot- ting. Compared with non-PBC cases and control cases, there were significant difference between these groups. The sensitivity of anti-gp210 and spl00 were 41.5% and 17.0%, respectively, and the specificity of anti-gp210 and sp100 were 97.2% and 99.5%, respectively. Conclusion Detection of anti-gp210 and spl00 has great significance in the diagnosis and treatment of PBC. Key words： Primary biliary cirrhosis; Anti-gp210 antibody; Anti-spl00 antibody